Table of Content

1 Secondary Progressive Multiple Sclerosis Drug Market Overview
1.1 Secondary Progressive Multiple Sclerosis Drug Product Overview
1.2 Secondary Progressive Multiple Sclerosis Drug Market Segment by Type
1.2.1 Inebilizumab
1.2.2 GLX-1112
1.2.3 DC-TAB
1.2.4 Etomoxir
1.2.5 IB-MS
1.2.6 Others
1.3 Global Secondary Progressive Multiple Sclerosis Drug Market Size by Type
1.3.1 Global Secondary Progressive Multiple Sclerosis Drug Market Size Overview by Type (2018-2034)
1.3.2 Global Secondary Progressive Multiple Sclerosis Drug Historic Market Size Review by Type (2018-2024)
1.3.3 Global Secondary Progressive Multiple Sclerosis Drug Forecasted Market Size by Type (2024-2034)
1.4 Key Regions Market Size Segment by Type
1.4.1 North America Secondary Progressive Multiple Sclerosis Drug Sales Breakdown by Type (2018-2024)
1.4.2 Europe Secondary Progressive Multiple Sclerosis Drug Sales Breakdown by Type (2018-2024)
1.4.3 Asia-Pacific Secondary Progressive Multiple Sclerosis Drug Sales Breakdown by Type (2018-2024)
1.4.4 Latin America Secondary Progressive Multiple Sclerosis Drug Sales Breakdown by Type (2018-2024)
1.4.5 Middle East and Africa Secondary Progressive Multiple Sclerosis Drug Sales Breakdown by Type (2018-2024)
2 Global Secondary Progressive Multiple Sclerosis Drug Market Competition by Company
2.1 Global Top Players by Secondary Progressive Multiple Sclerosis Drug Sales (2018-2024)
2.2 Global Top Players by Secondary Progressive Multiple Sclerosis Drug Revenue (2018-2024)
2.3 Global Top Players by Secondary Progressive Multiple Sclerosis Drug Price (2018-2024)
2.4 Global Top Manufacturers Secondary Progressive Multiple Sclerosis Drug Manufacturing Base Distribution, Sales Area, Product Type
2.5 Secondary Progressive Multiple Sclerosis Drug Market Competitive Situation and Trends
2.5.1 Secondary Progressive Multiple Sclerosis Drug Market Concentration Rate (2018-2024)
2.5.2 Global 5 and 10 Largest Manufacturers by Secondary Progressive Multiple Sclerosis Drug Sales and Revenue in 2022
2.6 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Secondary Progressive Multiple Sclerosis Drug as of 2022)
2.7 Date of Key Manufacturers Enter into Secondary Progressive Multiple Sclerosis Drug Market
2.8 Key Manufacturers Secondary Progressive Multiple Sclerosis Drug Product Offered
2.9 Mergers & Acquisitions, Expansion
3 Secondary Progressive Multiple Sclerosis Drug Status and Outlook by Region
3.1 Global Secondary Progressive Multiple Sclerosis Drug Market Size and CAGR by Region: 2018 VS 2022 VS 2034
3.2 Global Secondary Progressive Multiple Sclerosis Drug Historic Market Size by Region
3.2.1 Global Secondary Progressive Multiple Sclerosis Drug Sales in Volume by Region (2018-2024)
3.2.2 Global Secondary Progressive Multiple Sclerosis Drug Sales in Value by Region (2018-2024)
3.2.3 Global Secondary Progressive Multiple Sclerosis Drug Sales (Volume & Value) Price and Gross Margin (2018-2024)
3.3 Global Secondary Progressive Multiple Sclerosis Drug Forecasted Market Size by Region
3.3.1 Global Secondary Progressive Multiple Sclerosis Drug Sales in Volume by Region (2024-2034)
3.3.2 Global Secondary Progressive Multiple Sclerosis Drug Sales in Value by Region (2024-2034)
3.3.3 Global Secondary Progressive Multiple Sclerosis Drug Sales (Volume & Value), Price and Gross Margin (2024-2034)
4 Global Secondary Progressive Multiple Sclerosis Drug by Application
4.1 Secondary Progressive Multiple Sclerosis Drug Market Segment by Application
4.1.1 Hospital
4.1.2 Clinic
4.1.3 Others
4.2 Global Secondary Progressive Multiple Sclerosis Drug Market Size by Application
4.2.1 Global Secondary Progressive Multiple Sclerosis Drug Market Size Overview by Application (2018-2034)
4.2.2 Global Secondary Progressive Multiple Sclerosis Drug Historic Market Size Review by Application (2018-2024)
4.2.3 Global Secondary Progressive Multiple Sclerosis Drug Forecasted Market Size by Application (2024-2034)
4.3 Key Regions Market Size Segment by Application
4.3.1 North America Secondary Progressive Multiple Sclerosis Drug Sales Breakdown by Application (2018-2024)
4.3.2 Europe Secondary Progressive Multiple Sclerosis Drug Sales Breakdown by Application (2018-2024)
4.3.3 Asia-Pacific Secondary Progressive Multiple Sclerosis Drug Sales Breakdown by Application (2018-2024)
4.3.4 Latin America Secondary Progressive Multiple Sclerosis Drug Sales Breakdown by Application (2018-2024)
4.3.5 Middle East and Africa Secondary Progressive Multiple Sclerosis Drug Sales Breakdown by Application (2018-2024)
5 North America Secondary Progressive Multiple Sclerosis Drug by Country
5.1 North America Secondary Progressive Multiple Sclerosis Drug Historic Market Size by Country
5.1.1 North America Secondary Progressive Multiple Sclerosis Drug Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2034
5.1.2 North America Secondary Progressive Multiple Sclerosis Drug Sales in Volume by Country (2018-2024)
5.1.3 North America Secondary Progressive Multiple Sclerosis Drug Sales in Value by Country (2018-2024)
5.2 North America Secondary Progressive Multiple Sclerosis Drug Forecasted Market Size by Country
5.2.1 North America Secondary Progressive Multiple Sclerosis Drug Sales in Volume by Country (2024-2034)
5.2.2 North America Secondary Progressive Multiple Sclerosis Drug Sales in Value by Country (2024-2034)
6 Europe Secondary Progressive Multiple Sclerosis Drug by Country
6.1 Europe Secondary Progressive Multiple Sclerosis Drug Historic Market Size by Country
6.1.1 Europe Secondary Progressive Multiple Sclerosis Drug Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2034
6.1.2 Europe Secondary Progressive Multiple Sclerosis Drug Sales in Volume by Country (2018-2024)
6.1.3 Europe Secondary Progressive Multiple Sclerosis Drug Sales in Value by Country (2018-2024)
6.2 Europe Secondary Progressive Multiple Sclerosis Drug Forecasted Market Size by Country
6.2.1 Europe Secondary Progressive Multiple Sclerosis Drug Sales in Volume by Country (2024-2034)
6.2.2 Europe Secondary Progressive Multiple Sclerosis Drug Sales in Value by Country (2024-2034)
7 Asia-Pacific Secondary Progressive Multiple Sclerosis Drug by Region
7.1 Asia-Pacific Secondary Progressive Multiple Sclerosis Drug Historic Market Size by Region
7.1.1 Asia-Pacific Secondary Progressive Multiple Sclerosis Drug Market Size Growth Rate (CAGR) by Region: 2018 VS 2022 VS 2034
7.1.2 Asia-Pacific Secondary Progressive Multiple Sclerosis Drug Sales in Volume by Region (2018-2024)
7.1.3 Asia-Pacific Secondary Progressive Multiple Sclerosis Drug Sales in Value by Region (2018-2024)
7.2 Asia-Pacific Secondary Progressive Multiple Sclerosis Drug Forecasted Market Size by Region
7.2.1 Asia-Pacific Secondary Progressive Multiple Sclerosis Drug Sales in Volume by Region (2024-2034)
7.2.2 Asia-Pacific Secondary Progressive Multiple Sclerosis Drug Sales in Value by Region (2024-2034)
8 Latin America Secondary Progressive Multiple Sclerosis Drug by Country
8.1 Latin America Secondary Progressive Multiple Sclerosis Drug Historic Market Size by Country
8.1.1 Latin America Secondary Progressive Multiple Sclerosis Drug Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2034
8.1.2 Latin America Secondary Progressive Multiple Sclerosis Drug Sales in Volume by Country (2018-2024)
8.1.3 Latin America Secondary Progressive Multiple Sclerosis Drug Sales in Value by Country (2018-2024)
8.2 Latin America Secondary Progressive Multiple Sclerosis Drug Forecasted Market Size by Country
8.2.1 Latin America Secondary Progressive Multiple Sclerosis Drug Sales in Volume by Country (2024-2034)
8.2.2 Latin America Secondary Progressive Multiple Sclerosis Drug Sales in Value by Country (2024-2034)
9 Middle East and Africa Secondary Progressive Multiple Sclerosis Drug by Country
9.1 Middle East and Africa Secondary Progressive Multiple Sclerosis Drug Historic Market Size by Country
9.1.1 Middle East and Africa Secondary Progressive Multiple Sclerosis Drug Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2034
9.1.2 Middle East and Africa Secondary Progressive Multiple Sclerosis Drug Sales in Volume by Country (2018-2024)
9.1.3 Middle East and Africa Secondary Progressive Multiple Sclerosis Drug Sales in Value by Country (2018-2024)
9.2 Middle East and Africa Secondary Progressive Multiple Sclerosis Drug Forecasted Market Size by Country
9.2.1 Middle East and Africa Secondary Progressive Multiple Sclerosis Drug Sales in Volume by Country (2024-2034)
9.2.2 Middle East and Africa Secondary Progressive Multiple Sclerosis Drug Sales in Value by Country (2024-2034)
10 Company Profiles
10.1 AB Science SA
10.1.1 AB Science SA Company Information
10.1.2 AB Science SA Introduction and Business Overview
10.1.3 AB Science SA Secondary Progressive Multiple Sclerosis Drug Sales, Revenue and Gross Margin (2018-2024)
10.1.4 AB Science SA Secondary Progressive Multiple Sclerosis Drug Products Offered
10.1.5 AB Science SA Recent Development
10.2 Actelion Ltd
10.2.1 Actelion Ltd Company Information
10.2.2 Actelion Ltd Introduction and Business Overview
10.2.3 Actelion Ltd Secondary Progressive Multiple Sclerosis Drug Sales, Revenue and Gross Margin (2018-2024)
10.2.4 Actelion Ltd Secondary Progressive Multiple Sclerosis Drug Products Offered
10.2.5 Actelion Ltd Recent Development
10.3 Biogen, Inc.
10.3.1 Biogen, Inc. Company Information
10.3.2 Biogen, Inc. Introduction and Business Overview
10.3.3 Biogen, Inc. Secondary Progressive Multiple Sclerosis Drug Sales, Revenue and Gross Margin (2018-2024)
10.3.4 Biogen, Inc. Secondary Progressive Multiple Sclerosis Drug Products Offered
10.3.5 Biogen, Inc. Recent Development
10.4 F. Hoffmann-La Roche Ltd.
10.4.1 F. Hoffmann-La Roche Ltd. Company Information
10.4.2 F. Hoffmann-La Roche Ltd. Introduction and Business Overview
10.4.3 F. Hoffmann-La Roche Ltd. Secondary Progressive Multiple Sclerosis Drug Sales, Revenue and Gross Margin (2018-2024)
10.4.4 F. Hoffmann-La Roche Ltd. Secondary Progressive Multiple Sclerosis Drug Products Offered
10.4.5 F. Hoffmann-La Roche Ltd. Recent Development
10.5 Genzyme Corporation
10.5.1 Genzyme Corporation Company Information
10.5.2 Genzyme Corporation Introduction and Business Overview
10.5.3 Genzyme Corporation Secondary Progressive Multiple Sclerosis Drug Sales, Revenue and Gross Margin (2018-2024)
10.5.4 Genzyme Corporation Secondary Progressive Multiple Sclerosis Drug Products Offered
10.5.5 Genzyme Corporation Recent Development
10.6 Glialogix, Inc.
10.6.1 Glialogix, Inc. Company Information
10.6.2 Glialogix, Inc. Introduction and Business Overview
10.6.3 Glialogix, Inc. Secondary Progressive Multiple Sclerosis Drug Sales, Revenue and Gross Margin (2018-2024)
10.6.4 Glialogix, Inc. Secondary Progressive Multiple Sclerosis Drug Products Offered
10.6.5 Glialogix, Inc. Recent Development
10.7 Immune Response BioPharma, Inc.
10.7.1 Immune Response BioPharma, Inc. Company Information
10.7.2 Immune Response BioPharma, Inc. Introduction and Business Overview
10.7.3 Immune Response BioPharma, Inc. Secondary Progressive Multiple Sclerosis Drug Sales, Revenue and Gross Margin (2018-2024)
10.7.4 Immune Response BioPharma, Inc. Secondary Progressive Multiple Sclerosis Drug Products Offered
10.7.5 Immune Response BioPharma, Inc. Recent Development
10.8 Innate Immunotherapeutics Ltd
10.8.1 Innate Immunotherapeutics Ltd Company Information
10.8.2 Innate Immunotherapeutics Ltd Introduction and Business Overview
10.8.3 Innate Immunotherapeutics Ltd Secondary Progressive Multiple Sclerosis Drug Sales, Revenue and Gross Margin (2018-2024)
10.8.4 Innate Immunotherapeutics Ltd Secondary Progressive Multiple Sclerosis Drug Products Offered
10.8.5 Innate Immunotherapeutics Ltd Recent Development
10.9 Kyorin Pharmaceutical Co., Ltd.
10.9.1 Kyorin Pharmaceutical Co., Ltd. Company Information
10.9.2 Kyorin Pharmaceutical Co., Ltd. Introduction and Business Overview
10.9.3 Kyorin Pharmaceutical Co., Ltd. Secondary Progressive Multiple Sclerosis Drug Sales, Revenue and Gross Margin (2018-2024)
10.9.4 Kyorin Pharmaceutical Co., Ltd. Secondary Progressive Multiple Sclerosis Drug Products Offered
10.9.5 Kyorin Pharmaceutical Co., Ltd. Recent Development
10.10 Mallinckrodt Plc
10.10.1 Mallinckrodt Plc Company Information
10.10.2 Mallinckrodt Plc Introduction and Business Overview
10.10.3 Mallinckrodt Plc Secondary Progressive Multiple Sclerosis Drug Sales, Revenue and Gross Margin (2018-2024)
10.10.4 Mallinckrodt Plc Secondary Progressive Multiple Sclerosis Drug Products Offered
10.10.5 Mallinckrodt Plc Recent Development
10.11 MedDay SA
10.11.1 MedDay SA Company Information
10.11.2 MedDay SA Introduction and Business Overview
10.11.3 MedDay SA Secondary Progressive Multiple Sclerosis Drug Sales, Revenue and Gross Margin (2018-2024)
10.11.4 MedDay SA Secondary Progressive Multiple Sclerosis Drug Products Offered
10.11.5 MedDay SA Recent Development
10.12 MedImmune, LLC
10.12.1 MedImmune, LLC Company Information
10.12.2 MedImmune, LLC Introduction and Business Overview
10.12.3 MedImmune, LLC Secondary Progressive Multiple Sclerosis Drug Sales, Revenue and Gross Margin (2018-2024)
10.12.4 MedImmune, LLC Secondary Progressive Multiple Sclerosis Drug Products Offered
10.12.5 MedImmune, LLC Recent Development
10.13 Merck KGaA
10.13.1 Merck KGaA Company Information
10.13.2 Merck KGaA Introduction and Business Overview
10.13.3 Merck KGaA Secondary Progressive Multiple Sclerosis Drug Sales, Revenue and Gross Margin (2018-2024)
10.13.4 Merck KGaA Secondary Progressive Multiple Sclerosis Drug Products Offered
10.13.5 Merck KGaA Recent Development
10.14 Meta-IQ ApS
10.14.1 Meta-IQ ApS Company Information
10.14.2 Meta-IQ ApS Introduction and Business Overview
10.14.3 Meta-IQ ApS Secondary Progressive Multiple Sclerosis Drug Sales, Revenue and Gross Margin (2018-2024)
10.14.4 Meta-IQ ApS Secondary Progressive Multiple Sclerosis Drug Products Offered
10.14.5 Meta-IQ ApS Recent Development
10.15 Novartis AG
10.15.1 Novartis AG Company Information
10.15.2 Novartis AG Introduction and Business Overview
10.15.3 Novartis AG Secondary Progressive Multiple Sclerosis Drug Sales, Revenue and Gross Margin (2018-2024)
10.15.4 Novartis AG Secondary Progressive Multiple Sclerosis Drug Products Offered
10.15.5 Novartis AG Recent Development
10.16 Opexa Therapeutics, Inc.
10.16.1 Opexa Therapeutics, Inc. Company Information
10.16.2 Opexa Therapeutics, Inc. Introduction and Business Overview
10.16.3 Opexa Therapeutics, Inc. Secondary Progressive Multiple Sclerosis Drug Sales, Revenue and Gross Margin (2018-2024)
10.16.4 Opexa Therapeutics, Inc. Secondary Progressive Multiple Sclerosis Drug Products Offered
10.16.5 Opexa Therapeutics, Inc. Recent Development
10.17 Xenetic Biosciences (UK) Limited
10.17.1 Xenetic Biosciences (UK) Limited Company Information
10.17.2 Xenetic Biosciences (UK) Limited Introduction and Business Overview
10.17.3 Xenetic Biosciences (UK) Limited Secondary Progressive Multiple Sclerosis Drug Sales, Revenue and Gross Margin (2018-2024)
10.17.4 Xenetic Biosciences (UK) Limited Secondary Progressive Multiple Sclerosis Drug Products Offered
10.17.5 Xenetic Biosciences (UK) Limited Recent Development
11 Upstream, Opportunities, Challenges, Risks and Influences Factors Analysis
11.1 Secondary Progressive Multiple Sclerosis Drug Key Raw Materials
11.1.1 Key Raw Materials
11.1.2 Key Raw Materials Price
11.1.3 Raw Materials Key Suppliers
11.2 Manufacturing Cost Structure
11.2.1 Raw Materials
11.2.2 Labor Cost
11.2.3 Manufacturing Expenses
11.3 Secondary Progressive Multiple Sclerosis Drug Industrial Chain Analysis
11.4 Secondary Progressive Multiple Sclerosis Drug Market Dynamics
11.4.1 Secondary Progressive Multiple Sclerosis Drug Industry Trends
11.4.2 Secondary Progressive Multiple Sclerosis Drug Market Drivers
11.4.3 Secondary Progressive Multiple Sclerosis Drug Market Challenges
11.4.4 Secondary Progressive Multiple Sclerosis Drug Market Restraints
12 Market Strategy Analysis, Distributors
12.1 Sales Channel
12.2 Secondary Progressive Multiple Sclerosis Drug Distributors
12.3 Secondary Progressive Multiple Sclerosis Drug Downstream Customers
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.2 Data Source
14.2 Author Details
14.3 Disclaimer

List of Figure

List of Tables
Table 1. Major Company of Inebilizumab
Table 2. Major Company of GLX-1112
Table 3. Major Company of DC-TAB
Table 4. Major Company of Etomoxir
Table 5. Major Company of IB-MS
Table 6. Major Company of Others
Table 7. Global Secondary Progressive Multiple Sclerosis Drug Sales by Type 2018 VS 2022 VS 2034 (US$ Million)
Table 8. Global Secondary Progressive Multiple Sclerosis Drug Sales by Type (2018-2024) & (K Pcs)
Table 9. Global Secondary Progressive Multiple Sclerosis Drug Sales Market Share in Volume by Type (2018-2024)
Table 10. Global Secondary Progressive Multiple Sclerosis Drug Sales by Type (2018-2024) & (US& Million)
Table 11. Global Secondary Progressive Multiple Sclerosis Drug Market Share in Value by Type (2018-2024)
Table 12. Global Secondary Progressive Multiple Sclerosis Drug Price by Type (2018-2024) & (USD/Pcs)
Table 13. Global Secondary Progressive Multiple Sclerosis Drug Sales by Type (2024-2034) & (K Pcs)
Table 14. Global Secondary Progressive Multiple Sclerosis Drug Sales Market Share in Volume by Type (2024-2034)
Table 15. Global Secondary Progressive Multiple Sclerosis Drug Sales by Type (2024-2034) & (US$ Million)
Table 16. Global Secondary Progressive Multiple Sclerosis Drug Sales Market Share in Value by Type (2024-2034)
Table 17. Global Secondary Progressive Multiple Sclerosis Drug Price by Type (2024-2034) & (USD/Pcs)
Table 18. North America Secondary Progressive Multiple Sclerosis Drug Sales by Type (2018-2024) & (K Pcs)
Table 19. North America Secondary Progressive Multiple Sclerosis Drug Sales by Type (2018-2024) & (US$ Million)
Table 20. Europe Secondary Progressive Multiple Sclerosis Drug Sales (K Pcs) by Type (2018-2024)
Table 21. Europe Secondary Progressive Multiple Sclerosis Drug Sales by Type (2018-2024) & (US$ Million)
Table 22. Asia-Pacific Secondary Progressive Multiple Sclerosis Drug Sales (K Pcs) by Type (2018-2024)
Table 23. Asia-Pacific Secondary Progressive Multiple Sclerosis Drug Sales by Type (2018-2024) & (US$ Million)
Table 24. Latin America Secondary Progressive Multiple Sclerosis Drug Sales (K Pcs) by Type (2018-2024)
Table 25. Latin America Secondary Progressive Multiple Sclerosis Drug Sales by Type (2018-2024) & (US$ Million)
Table 26. Middle East and Africa Secondary Progressive Multiple Sclerosis Drug Sales (K Pcs) by Type (2018-2024)
Table 27. Middle East and Africa Secondary Progressive Multiple Sclerosis Drug Sales by Type (2018-2024) & (US$ Million)
Table 28. Global Secondary Progressive Multiple Sclerosis Drug Sales by Company (2018-2024) & (K Pcs)
Table 29. Global Secondary Progressive Multiple Sclerosis Drug Sales Share by Company (2018-2024)
Table 30. Global Secondary Progressive Multiple Sclerosis Drug Revenue by Company (2018-2024) & (US$ Million)
Table 31. Global Secondary Progressive Multiple Sclerosis Drug Revenue Share by Company (2018-2024)
Table 32. Global Market Secondary Progressive Multiple Sclerosis Drug Price by Company (2018-2024) & (USD/Pcs)
Table 33. Global Secondary Progressive Multiple Sclerosis Drug Top Manufacturers Manufacturing Base Distribution and Sales Area
Table 34. Global Secondary Progressive Multiple Sclerosis Drug Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 35. Global Top Manufacturers Market Share by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Secondary Progressive Multiple Sclerosis Drug as of 2022)
Table 36. Date of Key Manufacturers Enter into Secondary Progressive Multiple Sclerosis Drug Market
Table 37. Key Manufacturers Secondary Progressive Multiple Sclerosis Drug Product Type
Table 38. Mergers & Acquisitions, Expansion Plans
Table 39. Global Secondary Progressive Multiple Sclerosis Drug Market Size Comparison by Region (US$ Million): 2018 VS 2022 VS 2034
Table 40. Global Secondary Progressive Multiple Sclerosis Drug Sales by Region (2018-2024) & (K Pcs)
Table 41. Global Secondary Progressive Multiple Sclerosis Drug Sales Market Share in Volume by Region (2018-2024)
Table 42. Global Secondary Progressive Multiple Sclerosis Drug Sales by Region (2018-2024) & (US$ Million)
Table 43. Global Secondary Progressive Multiple Sclerosis Drug Sales Market Share in Value by Region (2018-2024)
Table 44. Global Secondary Progressive Multiple Sclerosis Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 45. Global Secondary Progressive Multiple Sclerosis Drug Sales by Region (2024-2034) & (K Pcs)
Table 46. Global Secondary Progressive Multiple Sclerosis Drug Sales Market Share in Volume by Region (2024-2034)
Table 47. Global Secondary Progressive Multiple Sclerosis Drug Sales by Region (2024-2034) & (US$ Million)
Table 48. Global Secondary Progressive Multiple Sclerosis Drug Sales Market Share in Value by Region (2024-2034)
Table 49. Global Secondary Progressive Multiple Sclerosis Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2024-2034)
Table 50. Global Secondary Progressive Multiple Sclerosis Drug Sales by Application: 2018 VS 2022 VS 2034 (US$ Million)
Table 51. Global Secondary Progressive Multiple Sclerosis Drug Sales by Application (2018-2024) & (K Pcs)
Table 52. Global Secondary Progressive Multiple Sclerosis Drug Sales Market Share in Volume by Application (2018-2024)
Table 53. Global Secondary Progressive Multiple Sclerosis Drug Sales by Application (2018-2024) & (US$ Million)
Table 54. Global Secondary Progressive Multiple Sclerosis Drug Sales Market Share in Value by Application (2018-2024)
Table 55. Global Secondary Progressive Multiple Sclerosis Drug Price by Application (2018-2024) & (USD/Pcs)
Table 56. Global Secondary Progressive Multiple Sclerosis Drug Sales by Application (2024-2034) & (K Pcs)
Table 57. Global Secondary Progressive Multiple Sclerosis Drug Sales Market Share in Volume by Application (2024-2034)
Table 58. Global Secondary Progressive Multiple Sclerosis Drug Sales by Application (2024-2034) & (US$ Million)
Table 59. Global Secondary Progressive Multiple Sclerosis Drug Sales Market Share in Value by Application (2024-2034)
Table 60. Global Secondary Progressive Multiple Sclerosis Drug Price by Application (2024-2034) & (USD/Pcs)
Table 61. North America Secondary Progressive Multiple Sclerosis Drug Sales by Application (2018-2024) (K Pcs)
Table 62. North America Secondary Progressive Multiple Sclerosis Drug Sales by Application (2018-2024) & (US$ Million)
Table 63. Europe Secondary Progressive Multiple Sclerosis Drug Sales by Application (2018-2024) (K Pcs)
Table 64. Europe Secondary Progressive Multiple Sclerosis Drug Sales by Application (2018-2024) & (US$ Million)
Table 65. Asia-Pacific Secondary Progressive Multiple Sclerosis Drug Sales by Application (2018-2024) (K Pcs)
Table 66. Asia-Pacific Secondary Progressive Multiple Sclerosis Drug Sales by Application (2018-2024) & (US$ Million)
Table 67. Latin America Secondary Progressive Multiple Sclerosis Drug Sales by Application (2018-2024) (K Pcs)
Table 68. Latin America Secondary Progressive Multiple Sclerosis Drug Sales by Application (2018-2024) & (US$ Million)
Table 69. Middle East and Africa Secondary Progressive Multiple Sclerosis Drug Sales by Application (2018-2024) (K Pcs)
Table 70. Middle East and Africa Secondary Progressive Multiple Sclerosis Drug Sales by Application (2018-2024) & (US$ Million)
Table 71. North America Secondary Progressive Multiple Sclerosis Drug Sales by Country (2018-2024) & (K Pcs)
Table 72. North America Secondary Progressive Multiple Sclerosis Drug Sales Market Share in Volume by Country (2018-2024)
Table 73. North America Secondary Progressive Multiple Sclerosis Drug Sales by Country (2018-2024) & (US$ Million)
Table 74. North America Secondary Progressive Multiple Sclerosis Drug Sales Market Share in Value by Country (2018-2024)
Table 75. North America Secondary Progressive Multiple Sclerosis Drug Sales by Country (2024-2034) & (K Pcs)
Table 76. North America Secondary Progressive Multiple Sclerosis Drug Sales Market Share in Volume by Country (2024-2034)
Table 77. North America Secondary Progressive Multiple Sclerosis Drug Sales by Country (2024-2034) & (US$ Million)
Table 78. North America Secondary Progressive Multiple Sclerosis Drug Sales Market Share in Value by Country (2024-2034)
Table 79. Europe Secondary Progressive Multiple Sclerosis Drug Sales by Country (2018-2024) & (K Pcs)
Table 80. Europe Secondary Progressive Multiple Sclerosis Drug Sales Market Share in Volume by Country (2018-2024)
Table 81. Europe Secondary Progressive Multiple Sclerosis Drug Sales by Country (2018-2024) & (US$ Million)
Table 82. Europe Secondary Progressive Multiple Sclerosis Drug Sales Market Share in Value by Country (2018-2024)
Table 83. Europe Secondary Progressive Multiple Sclerosis Drug Sales by Country (2024-2034) & (K Pcs)
Table 84. Europe Secondary Progressive Multiple Sclerosis Drug Sales Market Share in Volume by Country (2024-2034)
Table 85. Europe Secondary Progressive Multiple Sclerosis Drug Sales by Country (2024-2034) & (US$ Million)
Table 86. Europe Secondary Progressive Multiple Sclerosis Drug Sales Market Share in Value by Country (2024-2034)
Table 87. Asia-Pacific Secondary Progressive Multiple Sclerosis Drug Sales by Region (2018-2024) & (K Pcs)
Table 88. Asia-Pacific Secondary Progressive Multiple Sclerosis Drug Sales Market Share in Volume by Region (2018-2024)
Table 89. Asia-Pacific Secondary Progressive Multiple Sclerosis Drug Sales by Region (2018-2024) & (US$ Million)
Table 90. Asia-Pacific Secondary Progressive Multiple Sclerosis Drug Sales Market Share in Value by Region (2018-2024)
Table 91. Asia-Pacific Secondary Progressive Multiple Sclerosis Drug Sales by Region (2024-2034) & (K Pcs)
Table 92. Asia-Pacific Secondary Progressive Multiple Sclerosis Drug Sales Market Share in Volume by Region (2024-2034)
Table 93. Asia-Pacific Secondary Progressive Multiple Sclerosis Drug Sales by Region (2024-2034) & (US$ Million)
Table 94. Asia-Pacific Secondary Progressive Multiple Sclerosis Drug Sales Market Share in Value by Region (2024-2034)
Table 95. Latin America Secondary Progressive Multiple Sclerosis Drug Sales by Country (2018-2024) & (K Pcs)
Table 96. Latin America Secondary Progressive Multiple Sclerosis Drug Sales Market Share in Volume by Country (2018-2024)
Table 97. Latin America Secondary Progressive Multiple Sclerosis Drug Sales by Country (2018-2024) & (US$ Million)
Table 98. Latin America Secondary Progressive Multiple Sclerosis Drug Sales Market Share in Value by Country (2018-2024)
Table 99. Latin America Secondary Progressive Multiple Sclerosis Drug Sales by Country (2024-2034) & (K Pcs)
Table 100. Latin America Secondary Progressive Multiple Sclerosis Drug Sales Market Share in Volume by Country (2024-2034)
Table 101. Latin America Secondary Progressive Multiple Sclerosis Drug Sales by Country (2024-2034) & (US$ Million)
Table 102. Latin America Secondary Progressive Multiple Sclerosis Drug Sales Market Share in Value by Country (2024-2034)
Table 103. Middle East and Africa Secondary Progressive Multiple Sclerosis Drug Sales by Country (2018-2024) & (K Pcs)
Table 104. Middle East and Africa Secondary Progressive Multiple Sclerosis Drug Sales Market Share in Volume by Country (2018-2024)
Table 105. Middle East and Africa Secondary Progressive Multiple Sclerosis Drug Sales by Country (2018-2024) & (US$ Million)
Table 106. Middle East and Africa Secondary Progressive Multiple Sclerosis Drug Sales Market Share in Value by Country (2018-2024)
Table 107. Middle East and Africa Secondary Progressive Multiple Sclerosis Drug Sales by Country (2024-2034) & (K Pcs)
Table 108. Middle East and Africa Secondary Progressive Multiple Sclerosis Drug Sales Market Share in Volume by Country (2024-2034)
Table 109. Middle East and Africa Secondary Progressive Multiple Sclerosis Drug Sales by Country (2024-2034) & (US$ Million)
Table 110. Middle East and Africa Secondary Progressive Multiple Sclerosis Drug Sales Market Share in Value by Country (2024-2034)
Table 111. AB Science SA Company Information
Table 112. AB Science SA Introduction and Business Overview
Table 113. AB Science SA Secondary Progressive Multiple Sclerosis Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 114. AB Science SA Secondary Progressive Multiple Sclerosis Drug Product
Table 115. AB Science SA Recent Development
Table 116. Actelion Ltd Company Information
Table 117. Actelion Ltd Introduction and Business Overview
Table 118. Actelion Ltd Secondary Progressive Multiple Sclerosis Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 119. Actelion Ltd Secondary Progressive Multiple Sclerosis Drug Product
Table 120. Actelion Ltd Recent Development
Table 121. Biogen, Inc. Company Information
Table 122. Biogen, Inc. Introduction and Business Overview
Table 123. Biogen, Inc. Secondary Progressive Multiple Sclerosis Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 124. Biogen, Inc. Secondary Progressive Multiple Sclerosis Drug Product
Table 125. Biogen, Inc. Recent Development
Table 126. F. Hoffmann-La Roche Ltd. Company Information
Table 127. F. Hoffmann-La Roche Ltd. Introduction and Business Overview
Table 128. F. Hoffmann-La Roche Ltd. Secondary Progressive Multiple Sclerosis Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 129. F. Hoffmann-La Roche Ltd. Secondary Progressive Multiple Sclerosis Drug Product
Table 130. F. Hoffmann-La Roche Ltd. Recent Development
Table 131. Genzyme Corporation Company Information
Table 132. Genzyme Corporation Introduction and Business Overview
Table 133. Genzyme Corporation Secondary Progressive Multiple Sclerosis Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 134. Genzyme Corporation Secondary Progressive Multiple Sclerosis Drug Product
Table 135. Genzyme Corporation Recent Development
Table 136. Glialogix, Inc. Company Information
Table 137. Glialogix, Inc. Introduction and Business Overview
Table 138. Glialogix, Inc. Secondary Progressive Multiple Sclerosis Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 139. Glialogix, Inc. Secondary Progressive Multiple Sclerosis Drug Product
Table 140. Glialogix, Inc. Recent Development
Table 141. Immune Response BioPharma, Inc. Company Information
Table 142. Immune Response BioPharma, Inc. Introduction and Business Overview
Table 143. Immune Response BioPharma, Inc. Secondary Progressive Multiple Sclerosis Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 144. Immune Response BioPharma, Inc. Secondary Progressive Multiple Sclerosis Drug Product
Table 145. Immune Response BioPharma, Inc. Recent Development
Table 146. Innate Immunotherapeutics Ltd Company Information
Table 147. Innate Immunotherapeutics Ltd Introduction and Business Overview
Table 148. Innate Immunotherapeutics Ltd Secondary Progressive Multiple Sclerosis Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 149. Innate Immunotherapeutics Ltd Secondary Progressive Multiple Sclerosis Drug Product
Table 150. Innate Immunotherapeutics Ltd Recent Development
Table 151. Kyorin Pharmaceutical Co., Ltd. Company Information
Table 152. Kyorin Pharmaceutical Co., Ltd. Introduction and Business Overview
Table 153. Kyorin Pharmaceutical Co., Ltd. Secondary Progressive Multiple Sclerosis Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 154. Kyorin Pharmaceutical Co., Ltd. Secondary Progressive Multiple Sclerosis Drug Product
Table 155. Kyorin Pharmaceutical Co., Ltd. Recent Development
Table 156. Mallinckrodt Plc Company Information
Table 157. Mallinckrodt Plc Introduction and Business Overview
Table 158. Mallinckrodt Plc Secondary Progressive Multiple Sclerosis Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 159. Mallinckrodt Plc Secondary Progressive Multiple Sclerosis Drug Product
Table 160. Mallinckrodt Plc Recent Development
Table 161. MedDay SA Company Information
Table 162. MedDay SA Introduction and Business Overview
Table 163. MedDay SA Secondary Progressive Multiple Sclerosis Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 164. MedDay SA Secondary Progressive Multiple Sclerosis Drug Product
Table 165. MedDay SA Recent Development
Table 166. MedImmune, LLC Company Information
Table 167. MedImmune, LLC Introduction and Business Overview
Table 168. MedImmune, LLC Secondary Progressive Multiple Sclerosis Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 169. MedImmune, LLC Secondary Progressive Multiple Sclerosis Drug Product
Table 170. MedImmune, LLC Recent Development
Table 171. Merck KGaA Company Information
Table 172. Merck KGaA Introduction and Business Overview
Table 173. Merck KGaA Secondary Progressive Multiple Sclerosis Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 174. Merck KGaA Secondary Progressive Multiple Sclerosis Drug Product
Table 175. Merck KGaA Recent Development
Table 176. Meta-IQ ApS Company Information
Table 177. Meta-IQ ApS Introduction and Business Overview
Table 178. Meta-IQ ApS Secondary Progressive Multiple Sclerosis Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 179. Meta-IQ ApS Secondary Progressive Multiple Sclerosis Drug Product
Table 180. Meta-IQ ApS Recent Development
Table 181. Novartis AG Company Information
Table 182. Novartis AG Introduction and Business Overview
Table 183. Novartis AG Secondary Progressive Multiple Sclerosis Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 184. Novartis AG Secondary Progressive Multiple Sclerosis Drug Product
Table 185. Novartis AG Recent Development
Table 186. Opexa Therapeutics, Inc. Company Information
Table 187. Opexa Therapeutics, Inc. Introduction and Business Overview
Table 188. Opexa Therapeutics, Inc. Secondary Progressive Multiple Sclerosis Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 189. Opexa Therapeutics, Inc. Secondary Progressive Multiple Sclerosis Drug Product
Table 190. Opexa Therapeutics, Inc. Recent Development
Table 191. Xenetic Biosciences (UK) Limited Company Information
Table 192. Xenetic Biosciences (UK) Limited Introduction and Business Overview
Table 193. Xenetic Biosciences (UK) Limited Secondary Progressive Multiple Sclerosis Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 194. Xenetic Biosciences (UK) Limited Secondary Progressive Multiple Sclerosis Drug Product
Table 195. Xenetic Biosciences (UK) Limited Recent Development
Table 196. Key Raw Materials Lists
Table 197. Raw Materials Key Suppliers Lists
Table 198. Secondary Progressive Multiple Sclerosis Drug Market Trends
Table 199. Secondary Progressive Multiple Sclerosis Drug Market Drivers
Table 200. Secondary Progressive Multiple Sclerosis Drug Market Challenges
Table 201. Secondary Progressive Multiple Sclerosis Drug Market Restraints
Table 202. Secondary Progressive Multiple Sclerosis Drug Distributors List
Table 203. Secondary Progressive Multiple Sclerosis Drug Downstream Customers
Table 204. Research Programs/Design for This Report
Table 205. Key Data Information from Secondary Sources
Table 206. Key Data Information from Primary Sources
List of Figures
Figure 1. Secondary Progressive Multiple Sclerosis Drug Product Picture
Figure 2. Global Secondary Progressive Multiple Sclerosis Drug Market Size, 2018 VS 2022 VS 2034 (US$ Million)
Figure 3. Global Secondary Progressive Multiple Sclerosis Drug Market Size Status and Outlook (2018-2034) & (US$ Million)
Figure 4. Global Secondary Progressive Multiple Sclerosis Drug Sales Status and Outlook (2018-2034) & (K Pcs)
Figure 5. Product Picture of Inebilizumab
Figure 6. Global Inebilizumab Sales YoY Growth (2018-2034) & (K Pcs)
Figure 7. Product Picture of GLX-1112
Figure 8. Global GLX-1112 Sales YoY Growth (2018-2034) & (K Pcs)
Figure 9. Product Picture of DC-TAB
Figure 10. Global DC-TAB Sales YoY Growth (2018-2034) & (K Pcs)
Figure 11. Product Picture of Etomoxir
Figure 12. Global Etomoxir Sales YoY Growth (2018-2034) & (K Pcs)
Figure 13. Product Picture of IB-MS
Figure 14. Global IB-MS Sales YoY Growth (2018-2034) & (K Pcs)
Figure 15. Product Picture of Others
Figure 16. Global Others Sales YoY Growth (2018-2034) & (K Pcs)
Figure 17. Global Secondary Progressive Multiple Sclerosis Drug Sales by Type (2018-2034) & (US$ Million)
Figure 18. Global Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Type in 2022 & 2034
Figure 19. North America Secondary Progressive Multiple Sclerosis Drug Sales Market Share in Volume by Type in 2022
Figure 20. North America Secondary Progressive Multiple Sclerosis Drug Sales Market Share in Value by Type in 2022
Figure 21. Europe Secondary Progressive Multiple Sclerosis Drug Sales Market Share in Volume by Type in 2022
Figure 22. Europe Secondary Progressive Multiple Sclerosis Drug Sales Market Share in Value by Type in 2022
Figure 23. Asia-Pacific Secondary Progressive Multiple Sclerosis Drug Sales Market Share in Volume by Type in 2022
Figure 24. Asia-Pacific Secondary Progressive Multiple Sclerosis Drug Sales Market Share in Value by Type in 2022
Figure 25. Latin America Secondary Progressive Multiple Sclerosis Drug Sales Market Share in Volume by Type in 2022
Figure 26. Latin America Secondary Progressive Multiple Sclerosis Drug Sales Market Share in Value by Type in 2022
Figure 27. Middle East and Africa Secondary Progressive Multiple Sclerosis Drug Sales Market Share in Volume by Type in 2022
Figure 28. Middle East and Africa Secondary Progressive Multiple Sclerosis Drug Sales Market Share in Value by Type in 2022
Figure 29. The 5 and 10 Largest Manufacturers in the World: Market Share by Secondary Progressive Multiple Sclerosis Drug Sales in 2022
Figure 30. The 5 and 10 Largest Manufacturers in the World: Market Share by Secondary Progressive Multiple Sclerosis Drug Revenue in 2022
Figure 31. Secondary Progressive Multiple Sclerosis Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2018 VS 2022
Figure 32. Product Picture of Hospital
Figure 33. Global Hospital Sales YoY Growth (2018-2034) & (K Pcs)
Figure 34. Product Picture of Clinic
Figure 35. Global Clinic Sales YoY Growth (2018-2034) & (K Pcs)
Figure 36. Product Picture of Others
Figure 37. Global Others Sales YoY Growth (2018-2034) & (K Pcs)
Figure 38. Global Secondary Progressive Multiple Sclerosis Drug Sales by Application (2018-2034) & (US$ Million)
Figure 39. Global Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Application in 2022 & 2034
Figure 40. North America Secondary Progressive Multiple Sclerosis Drug Sales Market Share in Volume by Application in 2022
Figure 41. North America Secondary Progressive Multiple Sclerosis Drug Sales Market Share in Value by Application in 2022
Figure 42. Europe Secondary Progressive Multiple Sclerosis Drug Sales Market Share in Volume by Application in 2022
Figure 43. Europe Secondary Progressive Multiple Sclerosis Drug Sales Market Share in Value by Application in 2022
Figure 44. Asia-Pacific Secondary Progressive Multiple Sclerosis Drug Sales Market Share in Volume by Application in 2022
Figure 45. Asia-Pacific Secondary Progressive Multiple Sclerosis Drug Sales Market Share in Value by Application in 2022
Figure 46. Latin America Secondary Progressive Multiple Sclerosis Drug Sales Market Share in Volume by Application in 2022
Figure 47. Latin America Secondary Progressive Multiple Sclerosis Drug Sales Market Share in Value by Application in 2022
Figure 48. Middle East and Africa Secondary Progressive Multiple Sclerosis Drug Sales Market Share in Value by Application in 2022
Figure 49. Key Raw Materials Price
Figure 50. Secondary Progressive Multiple Sclerosis Drug Manufacturing Cost Structure
Figure 51. Secondary Progressive Multiple Sclerosis Drug Industrial Chain Analysis
Figure 52. Channels of Distribution
Figure 53. Distributors Profiles
Figure 54. Bottom-up and Top-down Approaches for This Report
Figure 55. Data Triangulation
Figure 56. Key Executives Interviewed